Checkpoint Inhibitors Under Investigation in Upper GI and Gastric Cancers

Jan 08, 2020

Aiwu Ruth He, MD, discusses the current role of immune checkpoint inhibitors in upper gastrointestinal and gastric cancers and which patients are most likely to benefit from the anti–PD-1 agents.

Aiwu Ruth He, MD, an associate professor of Medicine at Georgetown-Lombardi Comprehensive Cancer Center, discusses the current role of immune checkpoint inhibitors in upper gastrointestinal (GI) and gastric cancers and which patients are most likely to benefit from the anti—PD-1 agents.

For patients with upper GI or gastric cancer, the single-agent anti—PD-1 therapy nivolumab (Opdivo) is available in the chemotherapy-refractory setting. Patients need to have a combined positive score (CPS) greater than 1 to receive this therapy, He notes, as those patients tend to benefit from anti–PD-1 therapy.

Some clinical trials are also evaluating checkpoint inhibitors in the frontline andsecondlinesetting for patients with upper GI and gastric cancers. Initialdata

Related Content